TY - JOUR
T1 - Further insights into the pathophysiology of hyperapobetalipoproteinemia
T2 - Role of basic proteins I, II, III
AU - Kwiterovich, Pater O.
AU - Motevalli, Mahnaz
AU - Miller, Michael
AU - Bachorlk, Paul S.
AU - Kafonek, Stephanie D.
AU - Chatterjee, Subroto
AU - Beaty, Terri
AU - Virgil, Donna
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 1991
Y1 - 1991
N2 - Hyperapobetalipoproteinemia (hyperapoB), a familial lipoprotein disorder characterized by an increase in small, dense, low-density lipoprotein (LDL) particles, is strongly associated with coronary artery disease. There are two metabolic defects in hyperapoB: an increased synthesis of a very-low-density lipoprotein in liver, resulting in an overproduction of LDL, and a delayed clearance of post-prandial triglyceride and free fatty acids. To date, defects in the apolipoprotein B gene do not appear to explain the hyperapoB phenotype. Defect(s) in the uptake or intracellular metabolism of free fatty acids have been found in cells from hyperapoB patients. Three basic proteins (BPs) - BP I (Mr 14 000, pl 9.10), BP II (Mr 27 500, pl 8.48), and BP III (Mr 55 000, pi 8.73) - were isolated from normal human serum. Compared with normal fibroblasts, cultured hyperapoB fibroblasts incubated with BP I, which appears to be the same protein as acylation-stimulating protein (ASP), showed 50% less stimulation of triglyceride acylation and cholesterol esterification, whereas BP II markedly stimulated cholesteryl ester formation, and BP III caused no difference in response vs normal fibroblasts. However, in cultured normal human monocyte macrophages, BP III, but not BP I or BP II, stimulated cholesteryl esterification two- to threefold. BP I, BP II, and BP III may provide new insights into normal metabolism of lipids, lipoproteins, and free fatty acids and the pathophysiology of hyperapoB.
AB - Hyperapobetalipoproteinemia (hyperapoB), a familial lipoprotein disorder characterized by an increase in small, dense, low-density lipoprotein (LDL) particles, is strongly associated with coronary artery disease. There are two metabolic defects in hyperapoB: an increased synthesis of a very-low-density lipoprotein in liver, resulting in an overproduction of LDL, and a delayed clearance of post-prandial triglyceride and free fatty acids. To date, defects in the apolipoprotein B gene do not appear to explain the hyperapoB phenotype. Defect(s) in the uptake or intracellular metabolism of free fatty acids have been found in cells from hyperapoB patients. Three basic proteins (BPs) - BP I (Mr 14 000, pl 9.10), BP II (Mr 27 500, pl 8.48), and BP III (Mr 55 000, pi 8.73) - were isolated from normal human serum. Compared with normal fibroblasts, cultured hyperapoB fibroblasts incubated with BP I, which appears to be the same protein as acylation-stimulating protein (ASP), showed 50% less stimulation of triglyceride acylation and cholesterol esterification, whereas BP II markedly stimulated cholesteryl ester formation, and BP III caused no difference in response vs normal fibroblasts. However, in cultured normal human monocyte macrophages, BP III, but not BP I or BP II, stimulated cholesteryl esterification two- to threefold. BP I, BP II, and BP III may provide new insights into normal metabolism of lipids, lipoproteins, and free fatty acids and the pathophysiology of hyperapoB.
KW - Acylation-stimulating protein
KW - Apolipoproteins
KW - Basic proteins (BP)
KW - Cholesteryl ester formation
KW - Coronary artery disease
KW - Fibroblasts
KW - Lipoproteins
UR - http://www.scopus.com/inward/record.url?scp=0025765077&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025765077&partnerID=8YFLogxK
M3 - Article
C2 - 2004437
AN - SCOPUS:0025765077
SN - 0009-9147
VL - 37
SP - 317
EP - 326
JO - Clinical chemistry
JF - Clinical chemistry
IS - 3
ER -